Shopping Cart 0
Cart Subtotal
USD 0

Retinitis Pigmentosa: Competitive Landscape to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3495

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 6990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10485

Details

Retinitis Pigmentosa: Competitive Landscape to 2026

Summary

GlobalData's "Retinitis Pigmentosa: Competitive Landscape to 2026", combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

This report provides an assessment of the pipeline, clinical, and commercial landscape of RP. Overall, GlobalData expects new drug approvals, including gene therapy, stem cell therapy, and small molecule to drive RP market growth over the next decade (2016-2026).

Retinitis pigmentosa (RP) encompasses a heterogeneous group of rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors, and retinal pigment epithelium. Primary symptoms include night blindness and progressive vision field loss, eventually leading to blindness.

Scope

Components of the slide deck include-

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global RP market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RP market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Table Of Content

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

1.4 Upcoming Related Reports 5

2. Executive Summary 6

2.1 Key Findings 7

2.2 Key Events 8

3. Introduction 9

3.1 Report Scope 10

3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 14

4.1 Pipeline Overview 15

4.2 Pipeline Breakdown by Region/Country 17

4.3 Pipeline Products by Target/MOA Breakdown 18

4.4 Drug Review Designations 19

4.5 Products in Clinical Development 20

5. Clinical Trial Assessment 22

5.1 Clinical Trials Overview 23

5.2 Top Sponsors of Clinical Trials in Retinitis Pigmentosa 24

5.3 Trial Breakdown by Region 26

5.4 Therapy Area Perspective 27

5.5 Enrollment Analytics 28

6 Commercial Assessment 31

6.1 Leading Marketed Products 32

6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

7.1 Events Classification Overview 35

7.2 US 36

7.3 5EU 37

7.4 Japan, China, and India 38

8 Appendix 39

8.1 Sources 40

8.2 Methodology 42

8.3 Key Events Included in the Analysis 43

8.4 About the Authors 44

8.5 About GlobalData 47

8.6 Disclaimer 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Spark Therapeutics

Novartis

Neurotech Pharmaceuticals

Novelion Therapeutics

jCyte

Ocugen

Innovations In Sight

Horama

Neurotech Pharmaceuticals

Allergan

Company Profile

Company Profile Title

Retinitis Pigmentosa: Competitive Landscape to 2026

Summary

GlobalData's "Retinitis Pigmentosa: Competitive Landscape to 2026", combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

This report provides an assessment of the pipeline, clinical, and commercial landscape of RP. Overall, GlobalData expects new drug approvals, including gene therapy, stem cell therapy, and small molecule to drive RP market growth over the next decade (2016-2026).

Retinitis pigmentosa (RP) encompasses a heterogeneous group of rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors, and retinal pigment epithelium. Primary symptoms include night blindness and progressive vision field loss, eventually leading to blindness.

Scope

Components of the slide deck include-

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global RP market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RP market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

1.4 Upcoming Related Reports 5

2. Executive Summary 6

2.1 Key Findings 7

2.2 Key Events 8

3. Introduction 9

3.1 Report Scope 10

3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 14

4.1 Pipeline Overview 15

4.2 Pipeline Breakdown by Region/Country 17

4.3 Pipeline Products by Target/MOA Breakdown 18

4.4 Drug Review Designations 19

4.5 Products in Clinical Development 20

5. Clinical Trial Assessment 22

5.1 Clinical Trials Overview 23

5.2 Top Sponsors of Clinical Trials in Retinitis Pigmentosa 24

5.3 Trial Breakdown by Region 26

5.4 Therapy Area Perspective 27

5.5 Enrollment Analytics 28

6 Commercial Assessment 31

6.1 Leading Marketed Products 32

6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

7.1 Events Classification Overview 35

7.2 US 36

7.3 5EU 37

7.4 Japan, China, and India 38

8 Appendix 39

8.1 Sources 40

8.2 Methodology 42

8.3 Key Events Included in the Analysis 43

8.4 About the Authors 44

8.5 About GlobalData 47

8.6 Disclaimer 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Spark Therapeutics

Novartis

Neurotech Pharmaceuticals

Novelion Therapeutics

jCyte

Ocugen

Innovations In Sight

Horama

Neurotech Pharmaceuticals

Allergan